retatrutide triple agonist glp-1 gip glucagon phase 2 obesity Retatrutide, a GIP, and receptor agonist, for people with type diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, 2 trial conducted in the USA Diagram showing the mechanism of

[DOI] [PMC free article] [PubMed] [Google Scholar] 159.Butler AE, Campbell-Thompson M, Gurlo T, Dawson DW, Atkinson M, Butler PC

Do not take activated charcoal within 2 hours of any medication, including your GLP-1 injection, as it can reduce medication absorption

bariatric procedure volumes declined 11.4% in 2025 reversing a two-decade growth trend as semaglutide and tirzepatide provide comparable weight loss outcomes for class I and class II obesity without surgical risk, recovery time, or nutritional deficiency complications

doi: 10.1038/nrendo.2017.122

I will continue to use you going forward and recommend you to others

The story of GLP-1 medicines has taken decades and begins with the venom of a lizard, and the regulation of blood sugar